Phase 1B/2A safety, pharmacokinetics and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia

被引：0

作者：

Lin, Tara L.

Wood, Robyn

Ham, Tammy

Sullivan, Taegen

Dandawate, Prasad

Anant, Shrikant

Santaguida, Marianne T.

Toren, Paul

Jensen, Roy A.

Taylor, John A.

Baltezor, Michael Jay

Dalton, Michael

Meyer, Fred

McBride, John

Umbreit, Jay Nicholas

McCulloch, William

Vanderlaag, Kathryn

Wagner, Joseph

Weir, Scott James

Smith, B. Douglas

机构：

[1] Univ Kansas, Div Hematol Malignancies & Cellular Therapeut, Kansas City, KS USA

[2] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA

[3] CicloMed LLC, Kansas City, MO USA

[4] Tessa Pharmaceut LLC, Wake Forest, NC USA

[5] Univ Kansas Hlth Syst, Kansas City, KS USA

[6] Univ Kansas, Med Ctr, Dept Canc Biol, Kansas City, KS 66103 USA

[7] Notable Labs, Foster City, CA USA

[8] Childrens Mercy Hosp & Clin Kansas City, Kansas City, MO USA

[9] Univ Kansas, Ctr Canc, Kansas City, KS USA

[10] Univ Kansas, Med Ctr, Dept Urol, Kansas City, KS 66103 USA

[11] CritiTech Inc, Lawrence, KS USA

[12] Gnomon Grp, Carrboro, NC USA

[13] Inst Adv Med Innovat, Kansas City, KS USA

[14] Alliance Life Sci Advisors, Charlestown, MA USA

[15] Catalyst Clin Res, Wilmington, NC USA

[16] Alba BioPharm Advisors Inc, Raleigh, NC USA

[17] Univ Kansas, Inst Adv Med Innovat, Kansas City, KS USA

[18] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS7078

引用

页数：1

共 50 条

[1] Phase 1B/2A safety, pharmacokinetics, and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia.
Lin, Tara L.
Wood, Robyn
Ham, Tammy
Sullivan, Taegen
Bhattacharyya, Sangita
Dandawate, Prasad
Anant, Shrikant
Santaguida, Marianne T.
Zhang, Na
Toren, Paul
Jensen, Roy A.
Taylor, John A.
Baltezor, Michael Jay
Dalton, Michael
McBride, John
Umbreit, Jay Nicholas
McCulloch, William
Vanderlaag, Kathryn
Wagner, Joseph
Weir, Scott James
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[2] A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia
Lancet, Jeffrey E.
Roboz, Gail J.
Cripe, Larry D.
Michelson, Glenn C.
Fox, Judith A.
Leavitt, Richard D.
Chen, Tianling
Hawtin, Rachael
Craig, Adam R.
Ravandi, Farhad
Maris, Michael B.
Stuart, Robert K.
Karp, Judith E.
[J]. HAEMATOLOGICA, 2015, 100 (02) : 231 - 237
[3] Phase 1b/2 Pharmacokinetic/Pharmacodynamic (PK/PD) Study of Combination Voreloxin and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Patients
Lancet, Jeffrey E.
Roboz, Gail J.
Cripe, Larry D.
Maris, Michael
List, Alan F.
Fox, Judith
Michelson, Glenn C.
Karp, Judith
[J]. BLOOD, 2009, 114 (22) : 263 - 264
[4] Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study
Perl, Alexander E.
Daver, Naval G.
Pratz, Keith W.
Maly, Joseph
Hong, Wan-Jen
Bahceci, Erkut
Tong, Bo
Tian, Tian
Dilley, Kimberley
[J]. BLOOD, 2019, 134
[5] A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia
Jonas, Brian A.
Hou, Jing-Zhou
Roboz, Gail J.
Alvares, Caroline L.
Jeyakumar, Deepa
Edwards, John R.
Erba, Harry P.
Kelly, Richard J.
Roellig, Christoph
Fiedler, Walter
Brackman, Deanna
Siddani, Satya R.
Chyla, Brenda
Hilger-Rolfe, Jacqueline
Watts, Justin M.
[J]. HEMATOLOGICAL ONCOLOGY, 2023, 41 (04) : 743 - 752
[6] Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study
Usuki, Kensuke
Handa, Hiroshi
Choi, Ilseung
Yamauchi, Takahiro
Iida, Hiroatsu
Hata, Tomoko
Ohwada, Shoichi
Okudaira, Noriko
Nakamura, Kota
Sakajiri, Sakura
[J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (06) : 654 - 664
[7] Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study
Kensuke Usuki
Hiroshi Handa
Ilseung Choi
Takahiro Yamauchi
Hiroatsu Iida
Tomoko Hata
Shoichi Ohwada
Noriko Okudaira
Kota Nakamura
Sakura Sakajiri
[J]. International Journal of Hematology, 2019, 110 : 654 - 664
[8] Pharmacokinetics and pharmacodynamics of gilteritinib in patients with relapsed or refractory acute myeloid leukemia.
Smith, Catherine Choy
Levis, Mark J.
Litzow, Mark Robert
Perl, Alexander E.
Altman, Jessica K.
Gill, Stan
Yuen, Geoffrey
Bonate, Peter
Kadokura, Takeshi
James, Angela Joubert
Liu, Charles
Nagase, Itsuro
Fisniku, Ogert
Bahceci, Erkut
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[9] A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia
Griffiths, Elizabeth A.
Brady, William E.
Tan, Wei
Vigil, Carlos E.
Thompson, James E.
Ford, Laurie A.
Dickey, Noelle M.
Bashaw, Heather L.
Sperrazza, Jill
Wetzler, Meir
Wang, Eunice S.
[J]. LEUKEMIA RESEARCH, 2016, 43 : 44 - 48
[10] A Phase I Study of Lenalidomide and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Griffiths, Elizabeth A.
Brady, William
Tan, Wei
Vigil, Carlos E.
Thompson, James E.
Ford, Laurie A.
Dickey, Noelle M.
Sperrazza, Jill
Wang, Eunice S.
Wetzler, Meir
[J]. BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →